AMPLIFY: Manageable safety profile of acalabrutinib plus venetoclax with or without obinutuzumab in patients with treatment-naïve CLL

ASH 2024

Leukemia

AMPLIFY: Superior PFS with acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy in patients with treatment-naïve CLL

Leukemia

Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TN

Blood

Sharman JP, Egyed M, Jurczak W, Skarbnik AP, Patel K, Flinn IW, Kamdar M, Munir T, Walewska R, Hughes M, Fogliato LM, Herishanu Y, Banerji V, Follows GA, Walker PA, Ghia P, Janssens AM, Byrd JC, Ferrant EF, Ferrajoli A, Wierda WG, Wachira CW, Suterwala BT, Palhares de Miranda PA, Munugalavadla V, Wun CC, Woyach JA

doi: 10.1182/blood.2024024476

Leukemia

Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group

Leuk Lymphoma

Zielonka K, Izdebski B, Drozd-Sokołowska J, Pruszczyk-Matusiak K, Puła B, Wiśniewski K, Sawicki W, Kalicińska E, Jabłonowska-Babij P, Butrym A, Buczek T, Subocz E, Hałka J, Witkowska M, Wilk M, Hryniewiecka M, Gruenpeter K, Cichocka E, Halicki P, Wdowiak K, Iskierka-Jażdżewska E, Kopińska A, Szlauer-Stefańska A, Szymczyk A, Wolska-Washer A, Kowalczyk J, Wróbel T, Hus I, Jamroziak K

doi: 10.1080/10428194.2025.2535693

CHICAGO 2025

Gastrointestinal Cancer

BREAKWATER: Encorafenib plus cetuximab and mFOLFOX6 improves PFS and OS in treatment-naïve patients with BRAF V600E-mutant mCRC

SPECIAL REPORT

Breast Cancer

Managing Side Effects in Breast Cancer Treatment

Further Publications

Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 patients

Clin Cancer Res

Sato T, Butler MO, Piperno-Neumann S, Hassel JC, Nathan P, Shoushtari AN, Rutkowski P, Carvajal RD, Baurain JF, Schlaak M, Piulats JM, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, Ikeguchi A, Joshua AM, Middleton MR, Edukulla R, Pfeiffer C, Sacco JJ

doi: 10.1158/1078-0432.CCR-25-1513

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

COCOON Study: Enhanced dermatologic management reduces dermatologic adverse events with amivantamab plus lazertinib in patients with NSCLC harboring common EGFR mutations*

Leukemia

Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study

Br J Haematol

Ye Y, Liu X, Dai H, Hu J, Yu G, Zhang Y, Weng G, Lin D, Du X, Xiao J, Sun Z, Zhang H, Liang X, Guo Z, Xu N, Fan Z, Xuan L, Lin R, Yin Z, Huang F, Dai M, Li Z, Liu Q, Jin H

doi: 10.1111/bjh.20147

Lung, Respiratory and Thoracic Cancer

Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab

Lung Cancer

Ono S, Taniguchi H, Kuroda K, Hashimoto T, Okada A, Goto Y, Kitai H, Nakamura Y, Ogusu S, Hase T, Ota T, Ebi N, Furugen M, Harada T, Kinoshita Y, Mizoguchi T, Nakatomi K, Soejima Y, Yamada T, Takemoto S, Mukae H

doi: 10.1016/j.lungcan.2025.108709

Related content

AMPLIFY: Superior PFS with acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy in patients with treatment-naïve CLL

Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TN

Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group

BREAKWATER: Encorafenib plus cetuximab and mFOLFOX6 improves PFS and OS in treatment-naïve patients with BRAF V600E-mutant mCRC

Managing Side Effects in Breast Cancer Treatment

Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 patients

COCOON Study: Enhanced dermatologic management reduces dermatologic adverse events with amivantamab plus lazertinib in patients with NSCLC harboring common EGFR mutations*

Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study

Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab